Teva takes long-running ‘skinny label’ suit to SCOTUS

Generics giant’s petition cites the cost of medicine and first-principles of innovation.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Generic maker urges review of $235m skinny label decision

8 September 2022 A split Federal Circuit revived a 2017 jury verdict that Teva had infringed GSK drug | Israeli pharma firm warns of threat to availability of low-cost generic medicines.

Big Pharma

SCOTUS invites govt comment on Teva clash

4 October 2022 Court opens door for US solicitor general to file a brief | Hard fought ‘skinny label’ case centres on a generic medicine maker excluding patent-protected indications from its labels.

article

Teva loses plea against GSK’s $235m ‘skinny label’ win

16 May 2023 The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.

More on this story

Americas

Generic maker urges review of $235m skinny label decision

8 September 2022 A split Federal Circuit revived a 2017 jury verdict that Teva had infringed GSK drug | Israeli pharma firm warns of threat to availability of low-cost generic medicines.

Big Pharma

SCOTUS invites govt comment on Teva clash

article

Teva loses plea against GSK’s $235m ‘skinny label’ win

More on this story

Americas

Generic maker urges review of $235m skinny label decision

8 September 2022 A split Federal Circuit revived a 2017 jury verdict that Teva had infringed GSK drug | Israeli pharma firm warns of threat to availability of low-cost generic medicines.

Big Pharma

SCOTUS invites govt comment on Teva clash

article

Teva loses plea against GSK’s $235m ‘skinny label’ win